Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

apalutamide 1Radiotherapy 1Glutamyl Aminopeptidase 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) × Clear all
NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT05956639 2023-07-21

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

The First Affiliated Hospital with Nanjing Medical University

Phase 3 Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡